It is no easy task to estimate the cost-effectiveness of pharmaceuticals and medical devices. Some cases require calculation of the expense and survival years on a time span that extends beyond the period adopted for the clinical trials. In addition, analysis requires all sorts of data - the acquisition of which is by no means simple. We draw on specialized skills in areas such as modeling to analyze the cost-effectiveness of pharmaceuticals and medical devices.
- Model construction
- Cost-effectiveness analysis
- Cost-utility analysis
- Cost-benefit analysis
- Cost minimization analysis
- Database analysis
The value of pharmaceuticals and medical devices rises along with the social burden of the diseases they are designed to treat. Quantification of epidemiological information on items such as the number of patients - as well as the various burdens imposed on patients, families, and society as a whole - is essential for assessment of the value of pharmaceuticals and devices. We can also estimate the burden of illness. We utilize a broad range of information sources to quantify the socioeconomic burden of illness.
We are also entrusted with various statistical analyses. We can also execute analysis of data collected in clinical practice and meta-analysis of pooling published evidence. Valuable information may be mined from the mountains of data through our exploratory analyses.
- Statistical analysis
- Health-related quality of life (HRQOL)
- Conjoint analysis
- Analysis of willingness to pay
- Papers presenting the findings of pharmacoeconomic analyses make extensive use of terminology and concepts with which ordinary clinicians are unfamiliar. It may take a long time to gain a firm understanding of these complex model structures and the substance of cost-effectiveness. We also undertake outsourced development of software for interactive simulations through the application of animation and other technology. Even analyses that appear complicated can have relatively simple input and output. Similarly, the mechanisms of models that may be hard to comprehend when verbally described can be grasped directly through the experience of simulation.
Estimate of future medical costs in community areas
We estimate future risks pertaining to lifestyle-related diseases and relevant medical costs based on data on the population structure and health examinations in specific areas.
Assessment of disease management programs
We estimate the prospective effects of management programs for diabetes and other lifestyle-related diseases in order to reduce the risk of disease, and curtail medical costs, etc.